The Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients–Removing Excess Glucose trial (EMPA-REG OUTCOME) was the first CVOT to determine the cardiovascular benefits of SGLT2 inhibitors. The gene discussed is SLC5A2; the disease is diabetes mellitus.